<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00249288</url>
  </required_header>
  <id_info>
    <org_study_id>2004P-000495</org_study_id>
    <nct_id>NCT00249288</nct_id>
  </id_info>
  <brief_title>Folate Supplementation in Schizophrenia</brief_title>
  <official_title>Folate Supplementation in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine factors potentially contributing to differences in blood folate,
      homocysteine or B12 levels between schizophrenia patients, to test the hypothesis that low
      folate is associated with negative symptoms, and to examine the efficacy of folate
      supplementation for reducing negative symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a three-month, placebo-controlled trial of folate 2mg/d in 50 schizophrenia
      patients who score at least a 3 (moderate or greater severity) on at least one of the SANS
      global assessment subscales, with the exception of the attention global assessment subscale.
      The specific aims of this study are:

        -  To examine factors potentially contributing to differences in blood folate, homocysteine
           or B12 levels between patients at baseline, including dietary intake and cigarette
           smoking.

        -  To test the hypothesis that low folate is associated with negative symptoms by examining
           correlations between red blood cell folate concentrations and clinical ratings of
           negative symptoms and by comparing folate concentrations in deficit syndrome versus
           non-deficit syndrome patients. We will also control for dietary intake cigarettes
           smoking, gender, and age.

        -  To examine the efficacy of folate supplementation for reducing negative symptoms
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood Folate and Smoking Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood folate lab levels are reported by smoking status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood Folate and MTHFR Genotype</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood folate lab levels are reported by MTHFR genotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood Folate Levels and Dietary Intake</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood folate lab levels and dietary intake levels are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Folate Supplementation for Reducing Negative Symptoms as Measured by the SANS Modified Total</measure>
    <time_frame>Baseline score vs. week 12 score</time_frame>
    <description>The change from baseline to week 12 on the scale for the assessment of negative symptoms (SANS) modified total score. Total SANS scores range from 0-100. The SANS is comprised of 5 sub-scales: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each sub-scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the sub-scale total scores. To compute change in scores, baseline scores were subtracted from week 12 scores, resulting in a change score. Lower values signify greater improvement (i.e. week 12 score was lower than baseline score). The SANS modified total score is the SANS total score minus the Attention subscale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Serum B12 Levels and Smoking Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline serum B12 lab levels are reported by smoking status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Homocysteine Levels and Smoking Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood homocysteine lab levels are reported by smoking status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood B12 Levels and MTHFR Genotype</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood B12 lab levels are reported by MTHFR genotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood Homocysteine Levels and MTHFR Genotype</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood homocysteine lab levels are reported by MTHFR genotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Serum B12 Levels and Dietary Intake</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline serum B12 lab levels and dietary intake levels are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood Homocysteine Levels and Dietary Intake</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood homocysteine lab levels and dietary intake levels are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Baseline Blood Folate or B12 Levels and Dietary Intake</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood folate and B12 lab levels and dietary intake levels are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations Between Baseline Blood Folate and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood folate lab levels are reported by deficit syndrome status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations Between Baseline Blood B12 Levels and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood B12 lab levels are reported by deficit syndrome status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations Between Baseline Blood Homocysteine Levels and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood homocysteine lab levels are reported by deficit syndrome status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Folate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 2 mg/ day dose of folate, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 2 mg/ day dose of placebo, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folate</intervention_name>
    <description>Folic acid taken as 2, 1mg capsule daily for 12 weeks</description>
    <arm_group_label>Folate</arm_group_label>
    <other_name>Folate or folic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken as 2, 1mg capsule daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Schizophrenia, any subtype

          2. Ages 18-68

          3. Male or female

          4. A score at least a 3 (moderate or greater severity) on at least one of the SANS global
             assessment subscales, with the exception of the attention global assessment subscale

          5. Stable antipsychotic dose for &gt; 6 weeks

          6. Capable of providing informed consent

        Exclusion Criteria:

          1. Unstable medical illness

          2. Substance abuse

          3. Megaloblastic anemia

          4. Non-english speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald C. Goff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.schres-journal.com/article/S0920-9964(10)01680-4/abstract</url>
  </link>
  <results_reference>
    <citation>Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011 Apr;127(1-3):41-5. doi: 10.1016/j.schres.2010.12.006. Epub 2011 Feb 21.</citation>
    <PMID>21334854</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <results_first_submitted>June 11, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2014</results_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Donald C. Goff, MD</investigator_full_name>
    <investigator_title>Director of the Schizophrenia Clinical and Research Program</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Negative Symptoms</keyword>
  <keyword>Folate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty six participants were enrolled; 38 completed screening and 32 received study drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Folate</title>
          <description>Participants receiving 2 mg/daily of folate, for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Treatment</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received 2 mg/daily of placebo, for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Folate</title>
          <description>Patients underwent a 12 week trial of folate 2 mg/d</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="11.3"/>
                    <measurement group_id="B2" value="45.5" spread="9.6"/>
                    <measurement group_id="B3" value="46" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood Folate and Smoking Status</title>
        <description>Baseline blood folate lab levels are reported by smoking status.</description>
        <time_frame>Baseline</time_frame>
        <population>1 past smoker and 1 never smoker are missing RBC folate values. For the present analysis, as opposed to a comparison of treatment groups, folate levels are compared across smoking status.</population>
        <group_list>
          <group group_id="O1">
            <title>Current Smoker</title>
            <description>Study participants with current smoker status</description>
          </group>
          <group group_id="O2">
            <title>Past Smoker</title>
            <description>Participants with past smoker status</description>
          </group>
          <group group_id="O3">
            <title>Never Smoker</title>
            <description>Participants with never smoker status</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood Folate and Smoking Status</title>
          <description>Baseline blood folate lab levels are reported by smoking status.</description>
          <population>1 past smoker and 1 never smoker are missing RBC folate values. For the present analysis, as opposed to a comparison of treatment groups, folate levels are compared across smoking status.</population>
          <units>nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="3.3"/>
                    <measurement group_id="O2" value="14.6" spread="5.2"/>
                    <measurement group_id="O3" value="14.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614" spread="142"/>
                    <measurement group_id="O2" value="542" spread="122"/>
                    <measurement group_id="O3" value="475" spread="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood Folate and MTHFR Genotype</title>
        <description>Baseline blood folate lab levels are reported by MTHFR genotype.</description>
        <time_frame>Baseline</time_frame>
        <population>One participant with CC genotype is missing RBC folate value. For the present analysis, as opposed to a comparison of treatment groups, folate levels are compared across MTHFR genotype.</population>
        <group_list>
          <group group_id="O1">
            <title>CC Genotype</title>
            <description>Study participants with MTHFR genotype CC</description>
          </group>
          <group group_id="O2">
            <title>T- Genotype</title>
            <description>Participants with MTHFR genotype T (T allele carrier)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood Folate and MTHFR Genotype</title>
          <description>Baseline blood folate lab levels are reported by MTHFR genotype.</description>
          <population>One participant with CC genotype is missing RBC folate value. For the present analysis, as opposed to a comparison of treatment groups, folate levels are compared across MTHFR genotype.</population>
          <units>nanograms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="3.3"/>
                    <measurement group_id="O2" value="15.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624.8" spread="143.0"/>
                    <measurement group_id="O2" value="542.8" spread="150.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood Folate Levels and Dietary Intake</title>
        <description>Baseline blood folate lab levels and dietary intake levels are reported.</description>
        <time_frame>Baseline</time_frame>
        <population>All study participants at baseline. For the present analysis, as opposed to a comparison of treatment groups, folate levels are described for all participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>All study participants at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood Folate Levels and Dietary Intake</title>
          <description>Baseline blood folate lab levels and dietary intake levels are reported.</description>
          <population>All study participants at baseline. For the present analysis, as opposed to a comparison of treatment groups, folate levels are described for all participants at baseline.</population>
          <units>nanograms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="569.3" spread="148.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Folate Supplementation for Reducing Negative Symptoms as Measured by the SANS Modified Total</title>
        <description>The change from baseline to week 12 on the scale for the assessment of negative symptoms (SANS) modified total score. Total SANS scores range from 0-100. The SANS is comprised of 5 sub-scales: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each sub-scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the sub-scale total scores. To compute change in scores, baseline scores were subtracted from week 12 scores, resulting in a change score. Lower values signify greater improvement (i.e. week 12 score was lower than baseline score). The SANS modified total score is the SANS total score minus the Attention subscale.</description>
        <time_frame>Baseline score vs. week 12 score</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folate</title>
            <description>Participants will receive a 2 mg/ day dose of folate, for 12 weeks
Folate: Folic acid taken as 2, 1mg capsule daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
Placebo: Placebo taken by mouth daily as 2, 1mg capsule daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Folate Supplementation for Reducing Negative Symptoms as Measured by the SANS Modified Total</title>
          <description>The change from baseline to week 12 on the scale for the assessment of negative symptoms (SANS) modified total score. Total SANS scores range from 0-100. The SANS is comprised of 5 sub-scales: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each sub-scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the sub-scale total scores. To compute change in scores, baseline scores were subtracted from week 12 scores, resulting in a change score. Lower values signify greater improvement (i.e. week 12 score was lower than baseline score). The SANS modified total score is the SANS total score minus the Attention subscale.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="7.6"/>
                    <measurement group_id="O2" value="-9.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Serum B12 Levels and Smoking Status</title>
        <description>Baseline serum B12 lab levels are reported by smoking status.</description>
        <time_frame>Baseline</time_frame>
        <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are compared across smoking status.</population>
        <group_list>
          <group group_id="O1">
            <title>Current Smoker</title>
            <description>Study participants with current smoker status</description>
          </group>
          <group group_id="O2">
            <title>Past Smoker</title>
            <description>Participants with past smoker status</description>
          </group>
          <group group_id="O3">
            <title>Never Smoker</title>
            <description>Participants with never smoker status</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Serum B12 Levels and Smoking Status</title>
          <description>Baseline serum B12 lab levels are reported by smoking status.</description>
          <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are compared across smoking status.</population>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625" spread="273"/>
                    <measurement group_id="O2" value="436" spread="130"/>
                    <measurement group_id="O3" value="574" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Homocysteine Levels and Smoking Status</title>
        <description>Baseline blood homocysteine lab levels are reported by smoking status.</description>
        <time_frame>Baseline</time_frame>
        <population>1 participant who have never smoker status is missing plasma homocysteine values. For the present analysis, as opposed to a comparison of treatment groups, homocysteine levels are compared across smoking status.</population>
        <group_list>
          <group group_id="O1">
            <title>Current Smoker</title>
            <description>Study participants with current smoker status</description>
          </group>
          <group group_id="O2">
            <title>Past Smoker</title>
            <description>Participants with past smoker status</description>
          </group>
          <group group_id="O3">
            <title>Never Smoker</title>
            <description>Participants with never smoker status</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Homocysteine Levels and Smoking Status</title>
          <description>Baseline blood homocysteine lab levels are reported by smoking status.</description>
          <population>1 participant who have never smoker status is missing plasma homocysteine values. For the present analysis, as opposed to a comparison of treatment groups, homocysteine levels are compared across smoking status.</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.6"/>
                    <measurement group_id="O2" value="10.8" spread="1.6"/>
                    <measurement group_id="O3" value="9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood B12 Levels and MTHFR Genotype</title>
        <description>Baseline blood B12 lab levels are reported by MTHFR genotype.</description>
        <time_frame>Baseline</time_frame>
        <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are compared across MTHFR genotype.</population>
        <group_list>
          <group group_id="O1">
            <title>CC Genotype</title>
            <description>Study participants with MTHFR genotype CC</description>
          </group>
          <group group_id="O2">
            <title>T- Genotype</title>
            <description>Participants with MTHFR genotype T (T allele carrier)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood B12 Levels and MTHFR Genotype</title>
          <description>Baseline blood B12 lab levels are reported by MTHFR genotype.</description>
          <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are compared across MTHFR genotype.</population>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="605.5" spread="312.9"/>
                    <measurement group_id="O2" value="557.1" spread="170.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood Homocysteine Levels and MTHFR Genotype</title>
        <description>Baseline blood homocysteine lab levels are reported by MTHFR genotype.</description>
        <time_frame>Baseline</time_frame>
        <population>For the present analysis, as opposed to a comparison of treatment groups, homocystein levels are compared across MTHFR genotype.</population>
        <group_list>
          <group group_id="O1">
            <title>CC Genotype</title>
            <description>Study participants with MTHFR genotype CC</description>
          </group>
          <group group_id="O2">
            <title>T- Genotype</title>
            <description>Participants with MTHFR genotype T (T allele carrier)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood Homocysteine Levels and MTHFR Genotype</title>
          <description>Baseline blood homocysteine lab levels are reported by MTHFR genotype.</description>
          <population>For the present analysis, as opposed to a comparison of treatment groups, homocystein levels are compared across MTHFR genotype.</population>
          <units>micromoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="2.9"/>
                    <measurement group_id="O2" value="9.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Serum B12 Levels and Dietary Intake</title>
        <description>Baseline serum B12 lab levels and dietary intake levels are reported.</description>
        <time_frame>Baseline</time_frame>
        <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are described for all baseline participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>All study participants at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Serum B12 Levels and Dietary Intake</title>
          <description>Baseline serum B12 lab levels and dietary intake levels are reported.</description>
          <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are described for all baseline participants.</population>
          <units>picograms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566.6" spread="231.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood Homocysteine Levels and Dietary Intake</title>
        <description>Baseline blood homocysteine lab levels and dietary intake levels are reported.</description>
        <time_frame>Baseline</time_frame>
        <population>All study participants at baseline. For the present analysis, as opposed to a comparison of treatment groups, homocysteine levels are described for all baseline participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>All study participants at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood Homocysteine Levels and Dietary Intake</title>
          <description>Baseline blood homocysteine lab levels and dietary intake levels are reported.</description>
          <population>All study participants at baseline. For the present analysis, as opposed to a comparison of treatment groups, homocysteine levels are described for all baseline participants.</population>
          <units>micromoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Baseline Blood Folate or B12 Levels and Dietary Intake</title>
        <description>Baseline blood folate and B12 lab levels and dietary intake levels are reported.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants at baseline. For the present analysis, as opposed to a comparison of treatment groups, folate and B12 levels are described for all baseline participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>All study participants at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Baseline Blood Folate or B12 Levels and Dietary Intake</title>
          <description>Baseline blood folate and B12 lab levels and dietary intake levels are reported.</description>
          <population>All participants at baseline. For the present analysis, as opposed to a comparison of treatment groups, folate and B12 levels are described for all baseline participants.</population>
          <units>micrograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total folate, mcg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531.3" spread="386.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dietary folate, mcg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="765.7" spread="637.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Natural folate, mcg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.8" spread="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Synthetic folate, mcg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.4" spread="362.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total B12, mcg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlations Between Baseline Blood Folate and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</title>
        <description>Baseline blood folate lab levels are reported by deficit syndrome status.</description>
        <time_frame>Baseline</time_frame>
        <population>One deficit syndrome participant and one participant without deficit syndrome are missing RBC folate values. For the present analysis, as opposed to a comparison of treatment groups, folate levels are compared across deficit syndrome status.</population>
        <group_list>
          <group group_id="O1">
            <title>Deficit Syndrome</title>
            <description>Study participants with deficit syndrome</description>
          </group>
          <group group_id="O2">
            <title>Not Deficit Syndrome</title>
            <description>Participants without deficit syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Correlations Between Baseline Blood Folate and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</title>
          <description>Baseline blood folate lab levels are reported by deficit syndrome status.</description>
          <population>One deficit syndrome participant and one participant without deficit syndrome are missing RBC folate values. For the present analysis, as opposed to a comparison of treatment groups, folate levels are compared across deficit syndrome status.</population>
          <units>nanograms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="4.3"/>
                    <measurement group_id="O2" value="14.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC folate, ng/ml</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="585" spread="171"/>
                    <measurement group_id="O2" value="546" spread="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlations Between Baseline Blood B12 Levels and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</title>
        <description>Baseline blood B12 lab levels are reported by deficit syndrome status.</description>
        <time_frame>Baseline</time_frame>
        <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are compared across deficit syndrome status.</population>
        <group_list>
          <group group_id="O1">
            <title>Deficit Syndrome</title>
            <description>Study participants with deficit syndrome</description>
          </group>
          <group group_id="O2">
            <title>Not Deficit Syndrome</title>
            <description>Participants without deficit syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Correlations Between Baseline Blood B12 Levels and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</title>
          <description>Baseline blood B12 lab levels are reported by deficit syndrome status.</description>
          <population>For the present analysis, as opposed to a comparison of treatment groups, B12 levels are compared across deficit syndrome status.</population>
          <units>picograms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603" spread="193"/>
                    <measurement group_id="O2" value="513" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlations Between Baseline Blood Homocysteine Levels and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</title>
        <description>Baseline blood homocysteine lab levels are reported by deficit syndrome status.</description>
        <time_frame>Baseline</time_frame>
        <population>One participant without deficit syndrome is missing homocysteine. For the present analysis, as opposed to a comparison of treatment groups, homocysteine levels are compared across deficit syndrome status.</population>
        <group_list>
          <group group_id="O1">
            <title>Deficit Syndrome</title>
            <description>Study participants with deficit syndrome</description>
          </group>
          <group group_id="O2">
            <title>Not Deficit Syndrome</title>
            <description>Participants without deficit syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Correlations Between Baseline Blood Homocysteine Levels and Clinical Ratings of Negative Symptoms by Comparing Lab Levels in Deficit Syndrome Versus Non-deficit Syndrome Patients</title>
          <description>Baseline blood homocysteine lab levels are reported by deficit syndrome status.</description>
          <population>One participant without deficit syndrome is missing homocysteine. For the present analysis, as opposed to a comparison of treatment groups, homocysteine levels are compared across deficit syndrome status.</population>
          <units>micromoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="2.6"/>
                    <measurement group_id="O2" value="9.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Folate</title>
          <description>Participants receiving 2 mg/daily of folate, for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants receiving 2mg/daily of placebo, for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle Hill</name_or_title>
      <organization>Schizophrenia Program, Massachusetts General Hospital</organization>
      <phone>617-912-7846</phone>
      <email>michelehill1@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

